Thursday, May 30, 2019
Urogen started at Neutral, target $50, by Goldman Sachs
Goldman Sachs Group started coverage on shares of Urogen Pharma (NASDAQ:URGN) in a research report sent to investors on Wednesday morning, BenzingaRatingsTable reports. The brokerage issued a neutral rating and a $50.00 price objective on the stock.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.